Literature DB >> 19303302

Microsurgical treatment and functional outcomes of multi-segment intramedullary spinal cord tumors.

Jianjun Sun1, Zhenyu Wang, Zhendong Li, Bin Liu.   

Abstract

We aimed to prospectively analyze correlations between clinical features and histological classification of multi-segment intramedullary spinal cord tumors (MSICTs), and the extent of microsurgical resection and functional outcomes. Fifty-six patients with MSICTs underwent microsurgery for tumor removal using a posterior approach. The tumor was exposed through a dorsal myelotomy. Pre-operative and post-operative nervous function was scored using the Improved Japanese Orthopaedic Association (IJOA) grading system. Correlation analyses were performed between functional outcome (IJOA score) and histological features, age, tumor location, and the longitudinal extent of spinal cord involvement. The most frequently involved levels were the medullo cervical and the cervicothoracic regions (51.8%, 29/56) followed by the conus terminalis (26.8%, 15/56) and the thoracic region (14.3%, 8/56). Ependymoma was the most frequent MSICT type, seen in 22 of 56 patients (39%), followed by low grade astrocytoma (17 patients, 30%) and glioblastoma multiforme (3 patients, 5%). Gross total tumor removal was achieved in 33 cases (58%), subtotal resection in 4 (7%), and partial resection in 16 (28%). The histological classification of the tumor was the most important factor influencing the extent of surgical removal (chi2=22.17, p=0.00). The overall difference between pre-operative and post-operative neurological state was not significant (chi2=5.44, p=0.61). Thus, MSICTs were most commonly seen in the medullo cervical and cervicothoracic regions, with ependymoma and low grade astrocytoma the most common tumour types. We stress the importance of early microsurgical treatment for MSICTs while the patients do not have severe dysfunction.

Entities:  

Mesh:

Year:  2009        PMID: 19303302     DOI: 10.1016/j.jocn.2008.08.016

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  Comparative analysis on the diagnosis and treatments of multisegment intramedullary spinal cord tumors between the different age groups.

Authors:  Zhen-yu Wang; Jian-jun Sun; Jing-cheng Xie; Zhen-dong Li; Chang-cheng Ma; Bin Liu; Xiao-dong Chen; Hung-I Liao; Tao Yu; Jia Zhang
Journal:  Neurosurg Rev       Date:  2011-08-06       Impact factor: 3.042

2.  Treatment strategy for multisegmental cervicomedullary ependymoma: illustrative case.

Authors:  Andrei A Zrelov; Malik M Tastanbekov; Mikhail V Alexandrov; Anastasiia S Nechaeva; Olga A Toporkova; Olga M Vorobeva; Konstantin A Samochernykh
Journal:  J Neurosurg Case Lessons       Date:  2021-12-20

3.  Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group.

Authors:  Sun-Ho Lee; Chun Kee Chung; Chi Heon Kim; Sang Hoon Yoon; Seung-Jae Hyun; Ki-Jeong Kim; Eun-Sang Kim; Whan Eoh; Hyun-Jib Kim
Journal:  Neuro Oncol       Date:  2013-04-10       Impact factor: 12.300

4.  Comparative clinical study on seldom segment with multiple segment intramedullary primary spinal cord tumors.

Authors:  J J Sun; J Yang; J C Xie; Q Chang; C C Ma; M Zheng; H I Liao; T Wang; X D Chen; Y F Han; G Z Lin; T Yu; J Zhang; Y Si
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-10-18

5.  Glioblastoma multiforme in conus medullaris with intracranial metastasis after postoperative adjuvant therapy.

Authors:  Chengrui Yan; Xiangyi Kong; Hua Yin; Yu Wang; Huayu He; Hui Zhang; Jun Gao; Yongning Li; Wenbin Ma
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Intramedullary spinal cord tumors: A retrospective multicentric study.

Authors:  Anis Hachicha; Ala Belhaj; Nadhir Karmeni; Abdelhafidh Slimane; Sofiene Bouali; Jalel Kallel
Journal:  J Craniovertebr Junction Spine       Date:  2021-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.